Rationale for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathy

Click to increase image sizeClick to decrease image size

Declaration of interest

This work was supported in part by National Institutes of Health grants EY008976 and 5UM1AI110557, Center for Vision grant EY007003, and unrestricted grants from Research to Prevent Blindness and the Bell Charitable Foundation. T.J Smith is the holder of US patents 6936426, 7,998,681, 8,153,121, and 8,178,304 teaching about the IGF-1R as a target for therapy in autoimmune disease. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.